araag2/HINT huggingface dataset:
Clinical trial NCT00455429 (phase 2, status: terminated)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: placebo, jnj-26113100 (50 mg) once daily, jnj-26113100 (100 mg) once daily, jnj-26113100 (100 mg) twice daily, jnj-26113100 (250 mg) twice daily
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the study was stopped due to a non-clinical safety finding.
  
Eligibility criteria:

        Inclusion Criteria:-Adult participants with Atopic Dermatitis (skin rash, inflammation)
        involving greater than or equal to 10 percent body surface area

          -  Female participants must have a negative serum pregnancy test at screening

          -  With the exception of well-controlled asthma, allergic rhinitis and food allergies,
             participants must be in good general health prior to study participation with no
             clinically significant abnormalities as assessed by the investigator and determined by
             medical history, physical examination, blood chemistry, complete blood count,
             coagulation tests, urinalysis and electrocardiogram (ECG)

          -  Male subjects must consent to utilize a medically acceptable method of contraception
             throughout the study including the washout period and for three months after the study
             is completed

          -  Female participants of child bearing potential must consent to utilize a medically
             acceptable method of contraception throughout the study including the washout period
             and for three months after the study is completed Exclusion Criteria:-Evidence of
             clinically significant hepatic, reproductive, gastrointestinal, renal, hematologic,
             pulmonary, neurologic, respiratory (with the exception of well-controlled asthma),
             endocrine or cardiovascular abnormalities or psychiatric disorders

          -  Participants with screening alanine aminotransferase, alkaline phosphatase or direct
             bilirubin levels above the upper limit of normal

          -  Evidence of any skin condition that in the opinion of the investigator would interfere
             with assessment of atopic dermatitis

          -  Use of any investigational drugs within the previous 30 days prior to dosing or within
             a period of less than five times the drug's half-life, whichever is longer

          -  Use of any biologic within a period of 5 times its half-life
Clinical trial NCT01034657 (phase 2, status: terminated)
Conditions: myelodysplastic syndrome (mds)
ICD codes: D46.Z, D46.9, C94.6, D46.C
Drugs: lbh589, epoetin alfa
SMILES: [H]\C(=C(\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO, OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
Reason stopped: 
    the study was terminated due to lack of efficacy of single agent lbh589 in the 4 month open
    label core phase and due to enrollment difficulties.
  
Eligibility criteria:

        Key Inclusion Criteria:

          -  Patients with a lower risk MDS (LOW or INT-1 according to IPSS)

          -  Red blood cell transfusion dependency of at least 4 Units/8 weeks.

          -  Not responding to Erythropoietin stimulating agents (ESA) or having a low chance to do
             so

          -  Age-adjusted normal cardiac, kidney, liver function

        Key Exclusion Criteria:

          -  Concomitant use of ESA

          -  Concomitant use of any other investigational drug

          -  Other malignancy that is not in remission for at least 1 year

          -  Platelet Count < 75 x 109/L

          -  Impaired cardiac function or clinically significant cardiac diseases
Clinical trial NCT00098774 (phase 2, status: completed)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: cytarabine, etoposide, leucovorin calcium, methotrexate, temozolomide
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed newly diagnosed primary CNS lymphoma confirmed by 1 of the
             following methods:

               -  Brain biopsy or resection

               -  Cerebrospinal fluid (CSF) cytology

                    -  Positive CSF cytology with or without measurable intracranial disease

          -  No evidence of systemic non-Hodgkin's lymphoma

               -  CT scan or MRI of the chest, abdomen, and pelvis AND bilateral bone marrow biopsy
                  or unilateral biopsy with a 2cm core biopsy specimen that is negative for
                  extracerebral source of lymphoma

          -  Measurable contrast-enhancing disease by MRI of the brain and spine (plus gadolinium)
             unless CSF cytology positive

          -  No evidence of pleural effusions or ascites

        PATIENT CHARACTERISTICS:

        Age

          -  Any age

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count ≥ 1,500/mm^3

        Hepatic

          -  ALT and AST ≤ 2 times upper limit of normal

          -  Bilirubin ≤ 2 mg/dL

        Renal

          -  Creatinine clearance ≥ 50 mL/min

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for at least 6 months
             after study participation

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Concurrent steroids for the management of symptoms related to lymphoma allowed

        Radiotherapy

          -  No concurrent palliative radiotherapy

        Surgery

          -  Not specified
Clinical trial NCT00402883 (phase 2, status: terminated)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: bevacizumab, pemetrexed, carboplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    terminated due to bevacizumab and chemoradiotherapy toxicity
  
Eligibility criteria:

        Inclusion Criteria:

          -  Clinically confirmed non-small cell lung cancer stage IIIA and selected stage IIIB

          -  Measurable or evaluable disease

          -  Be up and about and able to care for self

          -  Adequate kidney, liver and bone marrow function

          -  No prior treatment for this disease

          -  Must be able to give written informed consent

          -  Must be able to take folic acid, vitamin B12 and dexamethasone as described in the
             protocol

          -  Age 18 years or older

        Exclusion Criteria:

          -  Stage IV or IIIB patients with pleural or pericardial effusions

          -  Stage IIIB disease with contralateral mediastinal nodes greater than 4cm

          -  Squamous cell predominant tumors

          -  Pregnant or lactating women

          -  Patients with active infections

          -  History of another cancer within the last 5 years with the exception of skin cancer or
             cervical carcinoma in situ

          -  History of stroke, transient ischemic attacks, or acute MI within the past 6 months or
             any other serious cardiovascular disease

          -  Symptoms of peripheral vascular disease

          -  History of neurological disease

          -  Recent history of blood in the sputum or vomitus

          -  Non-healing wounds, ulcer or long bone fractures

          -  History of bleeding problems or coagulation problems

          -  History of abdominal fistula, gastrointestinal perforation or intraabdominal abscess
             within 6 months

          -  History of uncontrolled hypertension

          -  Chronic use of non-steroidal anti-inflammatory medication not allowed on this study

        Please note: There are additional inclusion/exclusion criteria. The study center will
        determine if you meet all of the criteria. If you do not qualify for the trial, study
        personnel will explain the reasons. If you do qualify, study personnel will explain the
        trial in detail and answer any questions you may have. You can then decide if you wish to
        participate.
Clinical trial NCT00510822 (phase 2, status: completed)
Conditions: major depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: cimicoxib, placebo
SMILES: COC1=C(F)C=C(C=C1)C1=C(Cl)N=CN1C1=CC=C(C=C1)S(N)(=O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Major depression diagnosed by psychiatrist

          -  DSM IV TR: 296.2x single depressive episode or 296.3x recurrent depressive episode

          -  HamD-17 score ≥ 22

        Exclusion Criteria:

          -  Psychotic depression, bipolar disorder, obsessive compulsive disorder, anxiety
             disorder, personality disorder, drug or alcohol abuse, schizoaffective disorders,
             schizophrenia

          -  All DSM IV TR Axis-I disorders except depression

          -  All DSM IV TR Axis-II disorders without exception

          -  Unsuccessful treatment with more than 2 antidepressant medications

          -  Concomitant use of psychotropic drugs, including mood stabilizers

          -  Immediate risk of suicidal behaviour

          -  Women who are pregnant, breast feeding or planning to become pregnant during the
             course of study, Women who are not post-menopausal, surgically sterilized or using an
             effective method of contraception

          -  Any history of cardiovascular disease (e.g. angina, heart attack, stroke, congestive
             heart failure), uncontrolled high blood pressure, documented peripheral arterial
             insufficiency and symptomatic, clinically significant claudication, or a history of
             peripheral arterial embolism

          -  History of coronary heart disease (CHD) or any other heart disease

          -  History of upper or lower gastrointestinal (GI) ulceration, perforation and/or
             obstruction

          -  History of upper or lower GI bleeding within the previous year

          -  History of inflammatory bowel disease

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00459420 (phase 2/phase 3, status: completed)
Conditions: parkinson's disease, excessive daytime somnolence
ICD codes: G20
Drugs: caffeine 100-200 mg bid, placebo
SMILES: CN1C=NC2=C1C(=O)N(C)C(=O)N2C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  A diagnosis of idiopathic PD

          -  Excessive daytime somnolence (defined as an Epworth sleepiness scale score of >10).

        Exclusion Criteria:

          -  Estimated daily caffeine intake of more than 200 mg per day

          -  Active peptic ulcer disease

          -  Supraventricular cardiac arrhythmia (such as atrial fibrillation or atrial flutter)

          -  Uncontrolled hypertension - defined as systolic bp >170 or diastolic bp >110 on two
             consecutive readings

          -  EDS is caused by sleep apnea, restless legs syndrome, narcolepsy, shift work, or sleep
             promoting agents.

          -  Current use of prescribed alerting agents such as modafinil and methylphenidate

          -  Pre-menopausal women who are not using effective methods of birth control

          -  Dementia, defined as MMSE <24/30 and ADL impairment secondary to cognitive loss, or
             inability to understand consent process

          -  Depression, as defined by a Beck Depression Inventory score of >15.

          -  Changes to antiparkinsonian medication in the last 3 months, or changes to
             antiparkinsonian medication are anticipated during the study protocol.
Clinical trial NCT00501852 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: nva237, placebo, tiotropium
SMILES: C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female adults aged ≥40 years, who have signed an Informed Consent Form prior
             to initiation of any study-related procedure.

          -  Patients with moderate to severe COPD according to the Gold Guidelines (2006).

          -  Patients who have smoking history of at least 10 pack years. Ten pack-years is defined
             as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years etc.

          -  Patients with a post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥30%
             and < 80% of the predicted normal, and post-bronchodilator FEV1/forced vital capacity
             (FVC) < 0.7 at Visit 2. For non-Japanese patients predicted FEV1 should be calculated
             according to Quanjer predictive equations [Quanjer PH 1993], for Japanese patients
             predicted FEV1 should be calculated according to Japanese Respiratory Society
             predictive tables [Japan Respiratory Society 2001].

        Exclusion Criteria:

          -  Pregnant women or nursing mothers (pregnancy confirmed by positive urine pregnancy
             test).

          -  Patients requiring oxygen therapy on a daily basis for chronic hypoxemia, or who have
             been hospitalized for an exacerbation of their airways disease in the 6 weeks prior to
             Visit 1 or between Visit 1 and Visit 3.

          -  Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1.
             Patients who develop a respiratory tract infection during the screening period (up to
             Visit 3) must discontinue from the trial, but will be permitted to re-enroll at a
             later date (at least 6 weeks after the resolution of the respiratory tract infection).

          -  Patients who, in the judgment of the investigator or the responsible Novartis
             personnel, have a clinically relevant laboratory abnormality or a clinically
             significant condition such as (but not limited to) unstable ischemic heart disease,
             cancers, left ventricular failure, long term prednisone therapy, history of myocardial
             infarction, arrhythmia (all), narrow angle glaucoma, symptomatic prostatic hyperplasia
             or bladder-neck obstruction or moderate to severe renal impairment.

          -  Patients with a history of asthma indicated by (but not limited to):

               1. Blood eosinophil count > 400/mm3

               2. Onset of symptoms prior to age 40 years.

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00615758 (phase 2, status: completed)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: erlotinib
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed, unresectable locally advanced (stage IIIB
             with pleural effusion) and/or metastatic (stage IV) NSCLC

          -  No previous therapy for advanced/metastatic NSCLC is allowed

          -  age >18 years

          -  bidimensionally measurable disease

          -  non-smokers (or ex-smokers with less than 5 pack-years smoking history)

          -  adenocarcinoma histology

          -  performance status (WHO) 0-3

          -  adequate liver (serum bilirubin <1.5 times the upper normal limit (UNL); AST and ALT
             <2.5 times the UNL in the absence of demonstrable liver metastases, or <5 times the
             UNL in the presence of liver metastases); adequate renal function (serum creatinine
             <1.5 times the UNL); and bone marrow (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x
             109 /L) function

          -  previous radiotherapy, either in the adjuvant setting or for the treatment of
             metastatic disease is allowed provided that the measurable lesions are outside the
             radiation fields

          -  patient able to take oral medication

          -  tissue sample for tumour mutational analysis is required

        Exclusion Criteria:

          -  serious chronic skin conditions (e.g. psoriasis, eczema) that would preclude study
             participation

          -  active infection

          -  history of significant cardiac disease (unstable angina, congestive heart failure,
             myocardial infarction within the previous 6 months, ventricular arrhythmias)

          -  malnutrition (loss of ≥ 20% of the original body weight)

          -  performance status: 4

          -  psychiatric illness or social situation that would preclude study compliance

          -  pregnant or lactating women
Clinical trial NCT00581607 (phase 2/phase 3, status: completed)
Conditions: sarcoidosis, pulmonary arterial hypertension
ICD codes: D86.9, D86.2, D86.0, D86.3, D86.1, D86.89, D86.82, I27.21
Drugs: bosentan, placebo, bosentan, placebo
SMILES: COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with known sarcoidosis 21.

          -  Age 18 or greater

          -  Patients with documented pulmonary hypertension with a PA mean > 25 mm Hg as measured
             by cardiac catheterization within six months of entry into the study. Pulmonary artery
             occluding pressure and or left ventricular end diastolic pressure must be less than 15
             mm Hg.

          -  Patients with WHO class II or III

          -  Six minute walk distance of between 100 to 500 meters

          -  Patients on stable immunotherapy for their sarcoidosis, including prednisone,
             methotrexate, azathioprine, hydroxychloroquine, cyclophosphamide, thalidomide, and/or
             infliximab

          -  Patients able to provide written consent

        Exclusion Criteria:

          -  Patients on pulmonary vasodilator drugs (flolan, remodulin, bosentan, sildenafil) n
             the prior 28 days. Patients on stable dose of calcium channel blocker for more than 1
             month prior to right heart catheterization can be continued on the calcium channel
             blocker.

          -  Patients with severe airway obstruction as defined by FEV1/FVC of less than 35%

          -  Patients with World Health Organization (WHO) class IV status.

          -  Patients who are pregnant or breast feeding

          -  Patients with significant left ventricular dysfunction with a left ventricular
             ejection fraction of less than 35%

          -  Cardiac index < 2.0 liters and/or right atrial pressure >15 mm Hg

          -  Significant liver dysfunction not due to sarcoidosis.

          -  Patients with severe other organ disease felt by investigators to impact on survival
             during the course of the study.

          -  Patients unable to perform the 6 minute walk study
Clinical trial NCT00003223 (phase 2, status: terminated)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: fenretinide
SMILES: C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)NC1=CC=C(O)C=C1
Reason stopped: 
    closed due to poor accrual.
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically proven oral mucosal intraepithelial neoplasia Stage
        II: moderate dysplasia, keratosis with atypia Stage III: severe keratinizing or
        nonkeratinizing dysplasia No myelodysplastic syndrome No retinopathies

        PATIENT CHARACTERISTICS: See General Eligibility Criteria

        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy Chemotherapy: No
        concurrent chemotherapy Endocrine therapy: No concurrent endocrine therapy Radiotherapy: No
        concurrent radiotherapy Surgery: Prior surgical ablation of prior dysplastic sites allowed
        Other: At least 2 months since prior therapy toxicities Patient Characteristics-- Age: Not
        specified Performance Status: SWOG 0-1 Life Expectancy: Not specified Hematopoietic: Not
        specified Hepatic: Not specified Renal: Not specified Other: Not pregnant or nursing
        Negative pregnancy test Fertile patients must use effective contraception at least 1 month
        before, during, and at least 2 months after study
Clinical trial NCT00176228 (phase 2, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: lamotrigine
SMILES: NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Ages 10-20

          -  Must be able to swallow tablets

          -  Must be diagnosed with bipolar disorder

        Exclusion Criteria:

          -  Children with general medical condition such as head injury, epilepsy, endocrine
             disorders

          -  Those who are on mood altering medications such as steroids, and those diagnosed with
             mental retardation are excluded to avoid confounding and contributing factors to mood
             swings.

          -  If we discover during the interview that the parent and/or child does not understand
             the consent/assent procedures, we will exclude them.

          -  Girls who are pregnant or plan to become pregnant during the study period will also be
             excluded from the research. There have been no concerns raised in the literature about
             the need for birth control practices in males treated with lamotrigine. As such, there
             are no provisions to exclude males from the research who do not practice birth
             control.

        We expect only a small number of children to be excluded from the study due to exclusionary
        criteria. Selection of the subjects is not based on sex, race, or ethnic group.

        For the fMRI study:

          -  Given the limited size of the magnet bore, individuals with a body weight over
             two-hundred and fifty pounds will be unable to be tested within the MRI scanner.

          -  Women in the latter stages of pregnancy may be excluded due to large body size and
             potential discomfort while in the MRI apparatus. Please note that girls who are taking
             part in the drug portion of the study (this includes all female subjects except the 5
             healthy adult, control women) will be given 3 pregnancy during the drug study. This is
             to rule out pregnancy since pregnant girls should not be taking the study medications
             for safety reasons.

          -  Standard contraindications for fMRI studies include: cardiac pacemaker, aneurysm clip,
             cochlear implants, shrapnel, history of metal fragments in eyes, claustrophobia

          -  Participants with an IQ of less than 70 (assessed by WRAT) are likely to be excluded
             due to difficulties comprehending tasks and procedures